News

Doxorubicin Remains First-Line Standard for Metastatic Soft-Tissue Sarcomas

Publish date: October 15, 2012

 

AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY CONGRESS

The EORTC sponsored the trial. Dr. van der Graaf and Dr. Judson reported no conflicts of interest. Dr. Demetri reported financial relationships with several pharmaceutical companies.

Pages

Recommended Reading

Ridaforolimus Fails to Sway FDA Panel in Sarcoma Bid
MDedge Hematology and Oncology
ASCO: Stop Underdosing Obese Cancer Patients
MDedge Hematology and Oncology
Cixutumumab With Temsirolimus Slows Ewing's Sarcoma
MDedge Hematology and Oncology
FDA Approves Pazopanib for Advanced Soft-Tissue Sarcomas
MDedge Hematology and Oncology
Laparoscopy Tops Open Resection for Most Gastric Tumors
MDedge Hematology and Oncology
Regorafenib Delays Progression of Refractory Metastatic GIST
MDedge Hematology and Oncology
FDA Announces Limited Leucovorin Recall
MDedge Hematology and Oncology
FDA Warns of QT Prolongation with Ondansetron Dose
MDedge Hematology and Oncology
Washington Post Blasts Proliferation of ESAs for Anemia
MDedge Hematology and Oncology
Kaposi's Sarcoma Makes Unwelcome Return
MDedge Hematology and Oncology